Pulmatrix, Inc. (NASDAQ:PULM) Short Interest Update

Pulmatrix, Inc. (NASDAQ:PULM) was the recipient of a significant decrease in short interest in the month of September. As of September 30th, there was short interest totalling 5,100 shares, a decrease of 20.3% from the September 15th total of 6,400 shares. Based on an average trading volume of 11,000 shares, the short-interest ratio is currently 0.5 days. Approximately 0.1% of the shares of the stock are sold short.

Pulmatrix Price Performance

PULM stock traded down $0.02 during midday trading on Tuesday, hitting $2.09. The stock had a trading volume of 9,073 shares, compared to its average volume of 13,565. The company’s 50-day moving average price is $2.09 and its 200 day moving average price is $2.02. The firm has a market cap of $7.63 million, a PE ratio of -0.71 and a beta of 1.00. Pulmatrix has a 12-month low of $1.55 and a 12-month high of $2.75.

Pulmatrix (NASDAQ:PULM) last posted its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.87) EPS for the quarter. Pulmatrix had a negative net margin of 95.18% and a negative return on equity of 46.86%. The company had revenue of $1.55 million for the quarter.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on Pulmatrix in a report on Wednesday, October 9th. They set a “hold” rating for the company.

Pulmatrix Company Profile

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.